Regardless of the overall or PD-L1-positive advanced ESCC patients, nivolumab combined with chemotherapy or ipilimumab yielded near-equal health outcomes over a 10-year lifetime horizon estimation. Here, CD274 is linked to esophageal squamous cell carcinoma.